With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

Following a series of “most favored nation” (MFN) pricing deals with 17 large pharma companies, the Trump administration ...

In France, Wegovy is prescribed as a second-line treatment for obesity, not for people with a lower body mass index (BMI) or ...

In a bid to better deploy its boots-on-the-ground resources, the FDA is pulling back the curtain on a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to ...

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been ...

Sanofi is supercharging its artificial intelligence capabilities. | Sanofi is supercharging its artificial intelligence ...

Fresh off gaining an FDA expansion for Auvelity as a treatment for Alzheimer’s disease agitation (ADA), Axsome Therapeutics ...

In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany. | Novartis ...

The California-based biotech has hired Omeros and AbbVie alum Nadia Dac as its new chief commercial officer, where she will ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...